Katherine M Prioli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9089993/publications.pdf

Version: 2024-02-01

1478505 1281871 14 112 11 6 citations h-index g-index papers 14 14 14 172 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer. Journal of Geriatric Oncology, 2017, 8, 296-302.	1.0	35
2	Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model. Applied Health Economics and Health Policy, 2018, 16, 889-899.	2.1	17
3	Costâ€Effectiveness of a Communityâ€Integrated Homeâ€Based Depression Intervention in Older African Americans. Journal of the American Geriatrics Society, 2014, 62, 2288-2295.	2.6	13
4	Cost and Effectiveness of an Eye Care Adherence Program for Philadelphia Children with Significant Visual Impairment. Population Health Management, 2015, 18, 223-231.	1.7	11
5	Knowledge, Activation, and Costs of the Pharmacists' Pneumonia Prevention Program (PPPP): A Novel Senior Center Model to Promote Vaccination. Annals of Pharmacotherapy, 2018, 52, 446-453.	1.9	10
6	Cost–Benefit Analysis of the COPE Program for Persons Living With Dementia: Toward a Payment Model. Innovation in Aging, 2022, 6, igab042.	0.1	6
7	Pharmacists improve diabetes outcomes: a randomized controlled trial. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 775-782.e3.	1.5	6
8	Exploring beliefs about pneumococcal vaccination in a predominantly older African American population: the Pharmacists' Pneumonia Prevention Program (PPPP). Ethnicity and Health, 2021, 26, 364-378.	2.5	4
9	Cost of Purchased Versus Produced Plasma from Donor Recruitment Through Transfusion. Applied Health Economics and Health Policy, 2016, 14, 609-617.	2.1	2
10	Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review. Applied Health Economics and Health Policy, 2021, 19, 487-499.	2.1	2
11	Reducing the Costs of an Eye Care Adherence Program for Underserved Children Referred Through Inner-City Vision Screenings. American Journal of Ophthalmology, 2021, 227, 18-24.	3.3	2
12	Economic implications of FDA platelet bacterial guidance compliance options: Comparison of singleâ€step strategies. Transfusion, 2022, 62, 365-373.	1.6	2
13	Authors' Reply to Mintz: "Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model― Applied Health Economics and Health Policy, 2019, 17, 259-261.	2.1	1
14	Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports. American Health and Drug Benefits, 2020, 13, 136-142.	0.5	1